San Francisco, 13 December 2018: The Report Migraine Drugs Market Analysis Report By Therapeutic Class (Triptans, CGRP-based
Therapies, Ditans, Neurotoxins, NSAIDs), By Treatment, By Route of
Administration, And Segment Forecasts, 2018 - 2025
The global migraine drugs market size is expected to be valued at USD 7.8 billion by
2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0%
CAGR during the forecast period. The market is largely driven by factors such
as rise in disease prevalence, development of novel therapies, lifestyle
changes, and hormonal medications.
 |
| Migraine Drugs Market |
Migraine is a debilitating neurological
disease characterized by recurrent attacks of severe throbbing head pain
that can last for more than three days. Migraine pain may get worse on
movement, preventing the patient from carrying out normal, day-to-day
activities. In about one-third of attacks, both sides of the head, face, or
neck are affected.
Over the past five years, the global
migraine drugs market has been relatively stagnant, with the market mainly
dominated by usage of generic triptans and other off-label drugs. Majority of
the currently prescribed drugs for both acute and preventative treatment are
associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis’ CGRP mAb Aimovig
and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment
paradigm of migraine prevention. For drug manufacturers likely to enter the
market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing
will be a key differentiating factor as all CGRP-based therapies have a similar
efficacy and safety profile.
Access Research
Report of Migraine Drugs Market@ www.grandviewresearch.com/industry-analysis/migraine-drugs-market
Further key findings from the report suggest:
· Germany leads the European market, driven
by rising disease prevalence, novel drug launches, and increase in R&D
activities
· The acute migraine treatment market will be
supported by rapid uptake of novel drug classes such as CGRP receptor
antagonists and ditans currently under active investigation in multiple Phase
II/III trials
· Biohaven’s rimegepant is expected to face
competition from Allergan's ubrogepant, which has shown superior efficacy in
Phase III trials compared to rimegepant
· Eli Lilly’s Phase III 5-HT1F receptor
agonist Lasmiditan is expected to be a novel first-line non triptan acute
treatment option for patients in whom triptans are contradicted
· Approximately 20% of patients seeking
preventive treatment for migraine do not respond to available generic
medications. Several biologics and small molecules drugs are undergoing active
development to target high unmet needs in the preventive treatment segment
· Drugs with novel targets in early-phase
development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston
Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188
(combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant).
These novel agents are under evaluation for both episodic and chronic migraine
in multiple Phase I/II trials.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global migraine drugs market based on treatment, therapeutic class, route of
administration, and country:
Migraine Drugs Treatment Outlook (Revenue,
USD Million, 2017 - 2025)
·
Acute / Abortive Treatment
·
Preventive/ Prophylactic Treatment
Migraine Drugs Therapeutic Class
Outlook (Revenue, USD Million, 2017 - 2025)
·
Triptans
·
Acetylcholine Inhibitors
·
Ergot Alkaloids
·
NSAIDs
·
Ditans
·
CGRP small molecule antagonists
·
CGRP monoclonal antibodies
·
Others
Migraine Drugs Route of Administration
Outlook (Revenue, USD Million, 2017 - 2025)
·
Oral
·
Injectables
·
Others
Migraine Drugs Country Outlook (Revenue,
USD Million, 2017 - 2025)
·
U.S.
·
U.K.
·
France
·
Germany
·
Italy
·
Spain
·
Japan
Access Press Release of
Migraine
Drugs Market@ www.grandviewresearch.com/press-release/global-migraine-drugs-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment